AMOEBA Announces Filing of Universal Registration Document for 2023

AMOÉBA, a France-based biotech company specializing in microbiological risk treatment, declared the official filing of its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF). This submission, registered on April 29, 2024, under the number D.24-0352, encompasses details from the financial year which ended on December 31, 2023.

The disclosed document includes the annual financial report featuring consolidated and annual financial statements, a management report, and statutory auditors' reviews. It also contains a report on corporate governance prepared by the Board of Directors. AMOÉBA has made the Universal Registration Document 2023 accessible through its website and offers printed copies at its head office in Chassieu, France.